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Abstract 
8-Quinolinecarboxaldehyde selenosemicarbazone (H8qasesc) and its octahedral Co(III) 
complex were characterized by means of single crystal X-ray diffraction analysis, 
spectroscopy methods and cyclic voltammetry. Antineoplastic activity of the ligand and the 
complex has been assessed on acute monocytic leukemia cell line (THP-1) and AsPC-1 
cancer stem cell line (CSC) derived from patient suffering pancreatic adenocarcinoma, with 
cisplatin (CDDP) as a reference compound. Evaluation involved determination of pro-
apoptotic activity, changes in cell cycle distribution, role of caspase activation in process of 
cell death, and ability of investigated compounds to challenge reprogramming of CSC 
phenotype. Compared to CDDP, treatment with H8qasesc induced higher apoptotic response 
in both investigated cell lines. Apoptosis triggered by H8qasesc was highly caspase-
dependent, but did not include activation of either caspase-8 or -9. According to cell cycle 
changes H8qasesc delayed transition of cells during DNA replication, but in a manner 
different than CDDP. The ligand did not show nuclease activity on pUC19 plasmid, while 
docking studies disclosed that it does not have intercalating properties.  Treatment of THP-1 
cells with Co(III) complex resulted in strong toxic response, whereas cell death in treated 
AsPC-1 line was not achieved for 24 h. Additionally, the complex concentration-dependently 
digested plasmid DNA which might be the cause of its cytotoxic activity. Finally, H8qasesc 
successfully initiated reprogramming of CSC phenotype in AsPC-1 cell line. 
 
 
 
 
 
 
 
 
 
Page 2 of 29MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
06
 Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 C
ol
le
ge
 L
on
do
n 
on
 0
6/
06
/2
01
6 
17
:0
0:
31
. 
View Article Online
DOI: 10.1039/C6MD00199H
3 
 
1. INTRODUCTION 
Selenosemicarbazones are Schiff bases obtained by condensation reaction of carbonyl 
compounds and selenosemicarbazides. They showed antiparasitic,1 antifungal,2, 3 
antibacterial,3-6 antimalarial,7-10 anticancer,3, 7, 10-23 antioxidant3, 14 and antidiabetic14 activity. 
In order to obtain more active species, complexes of Pt(II), Pd(II), Zn(II), Cd(II), Au(I), 
Ni(II), Co(III), Ga(III), Sn(IV) and Cu(II) have been prepared and tested against malaria,10, 24, 
25 microorganisms,3-5 as well as cancer cell lines.3, 11, 16-23, 26 As a result of such approach 
metal complexes with activities better than corresponding ligands have been developed.3, 4, 19-
23, 26  
Despite the fact that investigation of biological activity of selenosemicarbazones 
started in the late fifties, apart from our research, up to now there are only three publications 
where mechanistic studies have been performed.11, 23, 27 First, Agrawal et. al. showed that 5-
hydroxy-2-formylpyridine selenosemicarbazone (5HPSe) caused marked inhibition of DNA 
synthesis in vitro, as measured by the incorporation of thymidine-methyl-3H, 5-3H-cytidine or 
adenine-8-14C  into DNA.11 It was shown that primary target of 5HPSe was ribonucleotide 
reductase (RR).  The recent study underlined the importance of reactive oxygen species 
(ROS) generation and activation of lysosomal apoptotic pathway through lysosomal 
membrane permeabilization (LMP) in the anticancer activity of 2-acetylpyridine 4,4-
dimethyl-3-selenosemicarbazone and demonstrated lysosomal targeting as a novel 
mechanism of selenosemicarbazone antiproliferative activity.27 
Biological properties of 2-formylpyridine selenosemicarbazone,  
2-quinolinecarboxaldehyde selenosemicarbazone, 8-quinolinecarboxaldehyde 
selenosemicarbazone and 2,6-diacetylpyridine bis(selenosemicarbazone) (Hfpsesc, Hqasesc, 
H8qasesc and H2dapsesc, respectively, Scheme 1) were systematically examined in our 
group.3, 17-20, 26 Monoselenosemicarbazones Hqasesc, Hfpsesc and H8qasesc had ability to act 
as anti-proliferative agents, inducing apoptosis and cell cycle perturbations in different 
malignant cell lines, while bis(selenosemicarbazone) H2dapsesc was far more active against 
normal than malignant cell lines, predominantly exerting necrotic cell death.3, 17-20, 26 The 
ligand Hqasesc induced growth inhibition in several cancer cell lines, although IC50 values 
were 2–10 times higher compared to those of cisplatin (CDDP). Being mostly successful on 
human cervical adenocarcinoma (HeLa) cells, Hqasesc triggered a significant increase of sub-
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G0/G1 cell population as compared to non-treated control that confirmed its ability to trigger 
apoptotic cell death.20 This ligand also caused strong concentration dependent apoptosis 
induction in acute monocytic leukemia (THP-1) cells, while in pancreatic adenocarcinoma 
cell line (AsPC-1) it induced apoptosis only at the highest concentration.26 The ligand 
Hfpsesc was tested on a wide range of malignant cell lines, such as human breast 
adenocarcinomas (MB-453 and MB-361), human osteosarcoma (U2Os) and its CDDP-
resistant sibling U2OS-Pt, HeLa cells, human melanoma (FemX), human colorectal 
adenocarcinoma (LS174), and murine melanoma (B16).19 Its activity revealed to be 
phenotype specific, with stronger inhibition of cell growth than CDDP on MDA-361, LS-
174, and B16 cells. In LS174, FemX and MDA-143 cell lines, treatment with Hfpsesc 
resulted in accumulation of cells in S-to-G2/M phase, while for U2OS and U2OS-Pt cells 
were accumulated exclusively in the S phase. The ligand H8qasesc showed the same degree 
of antiproliferative activity against U251 cell line as CDDP, with a 20 times higher 
antioxidant potential when compared to Vitamin C.3  
 
 
Scheme 1. Structures of mono- and bis(selenosemicarbazone) ligands. 
 
Preparation of Pt(II), Pd(II), Cd(II), Ni(II), Co(III) and Zn(II) complexes with  
Hqasesc and Hfpsesc, as well as Pt(II) and Pd(II)  complexes with H8qasesc resulted in 
compounds more potent than CDDP and the ligands themselves.3, 17-20 In general, 
monoselenosemicarbazone complexes induced apoptosis in all investigated cell lines.3, 17, 19, 
20, 26 In the case of bis selenosemicarbazone ligand H2dapsesc and its Cd(II) and Zn(II) 
complexes, neither caspase activity nor ROS production were induced in treated cells.18 More 
detailed mechanistic analysis of the action of Cd complex of Hqasesc revealed that it causes 
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cell cycle arrest in G0/G1 stage, massive caspases activation and production of ROS.3 The 
Zn(II) complex of Hqasesc interfered with DNA replication causing concentration-dependent 
apoptotic induction in THP-1 cells, which coincided with an arrest at the S phase of mitotic 
division.26 On the other hand, dramatically increased phosphorylation of extracellular 
receptor kinase, with recorded release of cytochrome C and activation of p73 in HeLa and 
MDA-361 cells treated with Hfpsesc and its Cd(II), Ni(II) and Zn(II) complexes, were 
detected.17 Ni(II) complex with Hfpsesc also showed potent anti-metastatic activity.16 Our 
studies have pointed out the importance of the nature of the metal ions in the mechanism of 
activity of selenosemicarbazone complexes. 
Cobalt is particularly suitable for complexation with selenosemicarbazones since it is 
biometal and already serves as co-factor in a number of natural enzymes.28, 29 In our previous 
work we synthesized Co(III) complex with Hqasesc ligand, [Co(qasesc)2]BF4, which did not 
show promising anticancer activity.19 In this complex, the ligand Hqasesc was tridentately 
(NNSe) coordinated, with the formation of two 5-membered chelate rings. Here we present 
the synthesis and characterization of a novel Co(III) complex with H8qasesc ligand, 
structural isomer of Hqasesc. Two isomers have the same mode of coordination, but 
H8qasesc is capable to form one 5-membered and 6-membered chelate rings. Our recent 
report indicates that chelate ring size may induce difference in biological activity of metal 
complexes.30 
In the current study, evaluation of anticancer potency of H8qasesc and its Co(III) 
complex was managed in order to investigate their pro-apoptotic activity on two malignant 
cell lines with pro-differentiation activity on cancer stem cells (CSCs). The human pancreatic 
adenocarcinoma AsPC-1 is expressing epithelial-masenchymal transition (EMT)-associated 
genes which promote tumor progression and metastasis, and designate this cell line as a good 
cancer stem cell model.31 CSCs are rare immortal cells within a tumor, dividing rapidly 
unlike stem cells of healthy tissues, and giving rise to resistance to therapy and tumor 
relapse.32 Results from experimental models and clinical studies showed that CSCs survive 
many commonly employed cancer treatments, giving them a high clinical relevance. 
Elimination of CSCs is set as the crucial need in intention to cure the cancer. For these 
reason, together with THP-1 cell line, we challenged our compounds against AsPC-1 cell line 
to evaluate their ability either to trigger apoptotic death and/or induce differentiation. 
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2. RESULTS & DISCUSSION 
2.1. Synthesis and characterization 
Cobalt(III) complex with N-heteroaromatic selenosemicarbazone ligand H8qasesc has 
been synthesized. The complex was prepared by template reaction starting from 
Co(ClO4)2×6H2O, 8qa and selenosemicarbazide (mole ratio 1 : 2 : 2, respectively). The 
complex is soluble in MeOH, EtOH, MeCN, DMF and DMSO at room temperature. Molar 
conductivity measurements showed that obtained complex is 1 : 1 type of electrolyte. Value 
of molar conductivity was unchanged after 24 h, indicating that complex is stabile in the 
solution. Elemental analysis showed that complex contains two deprotonated H8qasesc 
ligands, one perchlorate anion and one crystalline DMSO molecule. Concerning the all above 
mentioned, the following formula of novel Co(III) complex could be derived: 
[Co(8qasesc)2]ClO4×DMSO (1). The complex 1 is diamagnetic in nature which was 
confirmed by magnetic moment measurement at room temperature. The structure of 1 was 
elucidated by spectroscopic (IR, NMR and UV-Vis) and crystallographic methods. Since the 
ligand was obtained as a single-crystalline solid, its structure was determined by 
crystallographic methods also. Electrochemical behavior of the ligand and 1 was studied by 
cyclic voltammetry.  
In the IR spectrum of 1, shifts of the ν(C=N) toward higher frequencies (1604 cm–1 in 
H8qasesc and 1615 cm–1 in 1), and ν(C–Se) to lower frequencies (784 cm–1 in H8qasesc and 
761 cm–1 in 1) was noticed. The same frequency shift pattern was found for the ligand 
Hqasesc and its Co(III) complex, which was indication of coordination of imine nitrogen 
atom and selenium atom to Co(III).4 Also, in the IR spectrum of 1 the sharp and strong band 
at ~ 1068 cm‒1 originating from perchlorate ion can be observed.  
The labeling of atoms in H8qasesc used in NMR is given in Scheme 1. 1H NMR 
spectrum of 1 (Fig. S1A, ESI) shows that nitrogen atom N3 is deprotonated as evidenced by 
the absence of the H–N3 signal at 11.98 ppm in 1H NMR spectrum of H8qasesc. 
Coordination via the selenium atom can be seen by the strong upfield shift of C10 signal in 
13C NMR spectrum of 1 (Fig. S1B, ESI) in comparison to signal of the same carbon atom in 
the spectrum of metal-free H8qasesc. Coordination via the quinoline nitrogen atom can be 
observed by the upfield shift of H–C2, and downfield shifts of H–C4 and H–C5 in the 1H 
NMR spectrum of the complex 1. There is also an evidence for coordination via the quinoline 
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nitrogen atom in the 13C NMR spectrum, since signals of C2, C4 and C8a are shifted 
downfield.  Coordination via the azomethine nitrogen atom can be seen by the strong upfield 
shift of H–C9 in the 1H NMR spectrum of the complex, and by a downfield shift of C9 signal 
in the 13C NMR spectrum of the complex. There is also an interesting correlation in the 2D 
ROESY spectrum of 1 (Fig. S2, ESI), namely H–C2 is correlated with H–C9 and H–C7. This 
correlation points to the octahedral geometry of the complex, in which these atoms 
originating from two ligands are in proximity. This indicates that an octahedral geometry of 
the complex is preserved in the solution. 
The electronic spectrum of 1 (Fig. S3A, ESI) exhibits four bands in the region 222–
430 nm. Three bands, at 222, 296 and 354 nm, can be assigned to intra ligand n→π* 
transitions of the azomethine portion and π→π* transitions of the aromatic ring, while band at 
422 nm was assigned to the ligand to metal charge transfer transition. The same number of 
bands and distribution of their intensities was found for similar Co(III) complex with 2-
acetylpyridine thiosemicarbazone.33 The aqueous solution behavior of 1 with respect to 
hydrolysis was studied in DMSO/H2O 1:100 (v/v) solution at ambient temperature over 24 h 
by UV-Vis spectroscopy. The complex 1 was stable, as can be seen from its electronic 
absorption spectra (Fig. S3B, ESI). 
Electrochemical behavior of the ligand H8qasesc and 1 was studied by cyclic 
voltammetry in the potential range of ‒2.0 to +1.2 V vs Ag/AgCl electrode (Fig. S4, ESI). In 
the cyclic voltammogram of H8qasesc there are four well defined oxidation peaks at 
potentials of ‒0.382, +0.134, +0.48 and +0.994 V. By reduction of H8qasesc three peaks 
were observed at ‒0.03, ‒1.077 and ‒1.43 V. From these values it could be concluded that 
almost all observed peaks belong to the irreversible electrochemical reactions, and only redox 
couple at E1/2 = +0.07 V (oxidation at +0.134 V and reduction at ‒0.03 V) could be attributed 
to the quasi-reversible electrochemical processes. Under the same experimental conditions, 
two new well-defined peaks were observed in the cyclic voltammogram of 1. By comparison 
of the peak potentials one could conclude that shifts in peak positions can be attributed to the 
oxidation and reduction of electro-active groups from the ligand. Corresponding reduction 
peaks at ‒1.81 and ‒1.91 V represent reduction of Co(III) to Co(II) and the first oxidation 
peak at ‒1.78 V corresponds to the reverse  oxidation process. This implies that metal ion 
from the complex is easy accessible to the electrode surface. All presented results were 
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obtained after baseline background subtraction, to ensure that the observed peaks belong to 
the redox behavior of the complex. 
2.2. Description of crystal structures 
The molecular structures and atom numbering schemes of H8qasesc and 1 are shown 
in Fig. 1, while Table S1 (ESI) lists the pertinent X-ray crystallographic data for the two 
compounds. The ligand H8qasesc crystallizes in the monoclinic crystal system and P21/c 
space group, with four molecules in the unit cell. The selected bond lengths and angles for 
H8qasesc are shown in Table S2 (ESI). The molecule of H8qasesc can be considered as 
planar, with the highest displacement of N4 nitrogen atom (0.084 Å) from the root mean 
plane through all non-hydrogen atoms of the ligand. Dihedral angles (Table S3, ESI) 
confirmed planar geometry of the molecule. The crystal packing is dominated by hydrogen 
bonds (Fig. S5, ESI). 
The cobalt(III) ion coordinates two deprotonated H8qasesc ligands giving the 
octahedral bischelate cation [Co(8qaSeC)2]
+ with mer geometry (Fig. 1B). In the outer sphere 
of the complex, there is one perchlorate ion and one DMSO solvent molecule. The sulfur 
atom from the DMSO molecule is disordered over two sites with occupation factors 0.88 and 
0.12. Although the complex cation in 1 possesses a chiral octahedral arrangement, overall 1 is 
racemic compound since it crystallizes in the centric P-1 space group. The deprotonated 
ligand coordinates the metal in a tridentate fashion by means of the selenium atom, the 
quinoline and the imine nitrogen atoms, forming one six-membered and one five-membered 
chelate rings with the essentially planar ligand skeleton. The selenium donor atoms deviate 
slightly from the average planes formed by the ligands’ skeleton (0.35 and 0.19 Å 
respectively for Se1 and Se2). This slight distortion from planarity is due to an intramolecular 
repulsion between the selenium atoms which are forced by the bischelate coordination to 
come closer than the sum of their van der Waals radii (Se1…Se2 = 3.358(5) Å, rSe = 1.90Å). 
All metal-donor atom bonds (Table S2, ESI) are similar to the average corresponding bonds 
found in a search on quinoline thio/selenosemicarbazone-Co systems performed through the 
Cambridge Structural Database (CCDC: 734053; 2015 release, v. 5.36 with updates: Nov14, 
Feb15).34 The crystal packing of 1 (Fig. S6 and Table S4, ESI) is based on hydrogen bonds 
involving terminal NH2 groups, deprotonated hydrazinic nitrogen atom, perchlorate ions and 
DMSO molecules, as well as π-π stacking interactions of the quinoline rings. 
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Fig. 1. Molecular structure of H8qasesc (A) and [Co(8qasesc)2]
+  (1) (B) with the non-H 
atom numbering scheme (displacement ellipsoids at 40% probability level). 
 
 
2.3. Free radical scavenging activity  
Because selenium antioxidants can prevent oxidative damage, numerous animal and 
clinical trials have investigated the ability of these compounds to prevent the oxidative stress, 
an underlying cause of cancer. Interest in selone (C=Se) antioxidants can be attributed to the 
naturally occurring selenoneine, a compound that effectively scavenges 1,1-diphenyl-2-
picryl-hydrazyl (DPPH) radical.35 In our previous study we have determined the free radical-
scavenging activity of selenosemicarbazones and their metal complexes by ABTS method.3 
Our results showed that H8qasesc is an excellent ABTS cation radical-scavenger, with 
greater efficacy than Vitamin C. Coordination of the ligand to Pt(II) and Pd(II) canceled 
antioxidant activity of corresponding complexes.  
The proton donating ability of the H8qasesc and 1 was assayed using the DPPH 
method, a protocol for determination of radical scavenging activity.36 Ascorbic acid was used 
as the reference compound (50‒500 µg/mL). The results (expressed as IC50 in µM:  12.5 for 
Page 9 of 29 MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
06
 Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 C
ol
le
ge
 L
on
do
n 
on
 0
6/
06
/2
01
6 
17
:0
0:
31
. 
View Article Online
DOI: 10.1039/C6MD00199H
10 
 
H8qasesc, 5150 for 1 and 79.3 for Vitamin C) corroborate our previous finding by mean of 
ABTS method. The ligand H8qasesc has an excellent free radical-scavenging activity, better 
than the reference molecule Vitamin C. On the other hand, coordination of H8qasesc to 
Co(III) diminished the activity of corresponding complex. 
2.4. H8qasesc stimulated stronger apoptotic response compared to 1 and CDDP 
The ability of H8qasesc and 1 to induce death of THP1 and AsPC1 cells was tested in a span 
of six concentrations after 24 h of incubation. At the end of the treatment, cells were stained 
with Annexin-V and propidium iodide (PI), in order to determine percentages of viable and 
dead cells in analyzed samples. Initially applied concentration of H8qasesc on THP-1 cells in 
the range 1–100 µM induced extremely high apoptotic response (data not shown), thus those 
data described only the top plateau of the concentration-response sigmoidal curve while ED50 
concentration could not be calculated. For that reason, concentrations of H8qasesc were 
decreased for THP-1 cells up to 0.5 µM. As represented in Fig. 2A, most of apoptotic events 
in the samples treated with 30 and 10 µM were in advanced stages of apoptosis, which means 
that H8qasesc easily induced cells to execute an apoptotic death. Moreover, percentages of 
necrotic events were barely above the control levels. Herein, the ED50 value was easily 
calculated and applied in all following experiments on THP-1 cells (Fig. S7, ESI). 
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Fig. 2. Activity of H8qasesc on THP-1 cells and AsPC-1 cell lines. Annexin-V and 
propidium iodide (PI) double staining (left panels) and PI single staining (right panels) of 
THP-1(A) and AsPC-1 (B) cells after 24 h treatment with H8qasesc applied in a range of six 
concentrations. In Annexin-V/PI plots cells are discriminated as viable (non-stained cells, 
lower left quadrant), cells in early phases of apoptosis (Annexin-V single stained cells, lower 
right quadrant), cells in late phases of apoptosis (double-stained cells, upper right quadrant), 
and cells in necrosis (PI single stained cells, upper left quadrant). The same cells evaluated 
with Annexin-V/PI were fixed in ethanol right after analysis, left overnight and afterwards 
assayed for distribution within phases of mitotic division with PI single staining method. 
Frequency of cells found in G0/G1, S and G2/M phases was determined according to non-
treated control population. All results are expressed as the mean % ± SD of two replicates 
from independent experiments for THP-1 cells. Results for AsPC-1 cells are represented as a 
single replicate considering the second experiment was not performed due to low activity of 
H8qasesc on this cell line. 
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Incubation with 1 induced apoptosis as well (Fig. S8A, ESI), with some differences in 
response of THP1 cells therefore requiring more attention. First, percentages of apoptotic 
cells were gradually declining with decrease of 1 concentration, but even at 1 µM the 
incidence of double stained cells was higher compared to those single-stained with Annexin-
V. Second, 1 also induced necrotic cell death that exceeded 10% in the samples treated with 
100 and 75 µM which was progressively reducing with decrease of applied concentration, but 
remained persistent and surpassed 1% even at concentration of 1 µM. Such readout indicates 
on cellular toxicity of investigated compound, and in order to better observe its activity 
profile we performed additional testing with 1 applied in lower concentrations. In the samples 
treated with 0.5‒3 µM almost the same percentages of cells in necrosis, early and late stages 
of apoptosis were found (Fig. S8B, ESI). The lack of correlation between applied 
concentration of 1 and incidence of both types of cell death in treated samples clearly 
signifies that 1 does not display concentration-dependent activity, but rather intrinsic toxicity. 
Since these results showed that 1 possess undesirable profile of activity, additional 
experiment for the second replicate has not been performed. Cisplatin (CDDP) was used as a 
reference compound, considering it is also the metal complex highly efficient against various 
types of cancer. In 24 h of incubation on THP-1 cells with a concentration span (1–75 µM), 
CDDP concentration-dependently induced increase in percentage of cells entering apoptotic 
death (Figs S7 and S9, ESI). However, contrary to 1, only a small portion of apoptotic cells 
were conducted into advanced phases of apoptosis, and as well contrary to 1, CDDP did not 
induce significant increase of necrotic events.  
Quite the opposite to the effect seen on THP-1 cell line, on AsPC1 cells the ligand 
H8qasesc induced noteworthy increase of apoptotic events only at the highest applied 
concentration of 100 µM (Fig. 2B). However, some incidence of cell death was seen in the 
sample treated with concentration of 75 µM, but those cells were either PI single-stained or 
double stained, while the percentage of pre-apoptotic events was on the level of non-treated 
control. It is important to notice that according to control samples, AsPC1 cells contrary to 
THP-1 cell line spontaneously enter necrosis rather than apoptosis, thus only compound that 
acts as strong apoptosis inducer would lead AsPC1 cells to advanced stages of apoptotic 
death. Considering the lack of early apoptotic events, double-stained cells in the sample 
treated with H8qasesc at 75 µM more probably belonged to necrotic instead of cells in 
advanced stages of apoptosis,37 as a result of weak pro-apoptotic stimuli. Contrary, treatment 
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with H8qasesc at 100 µM has easily driven AsPC-1 cells from the initial to advanced stages 
of apoptotic death, while percentage of PI single-stained events remained equal to that after 
treatment with 75 µM. Estimated ED50 concentration for H8qasesc was above maximally 
applied 100 µM, while the same could not be calculated for 1 and CDDP due to their 
inactivity on AsPC-1 cell line. 
2.5. H8qasesc and CDDP induced different alterations in cell cycle distribution 
Changes in cell cycle distribution have been evaluated on the same cell populations 
that were previously analyzed for pro-apoptotic activity of investigated compounds. 
Considering that 1 showed undesirable activity profile on THP-1 cells and lack of activity on 
AsPC-1 cell line, distribution within phases of cell cycle division was evaluated on cells 
treated with H8qasesc on the both cell lines, and CDDP on THP-1 cells. The ligand H8qasesc 
induced concentration-dependent accumulation of THP-1 cells at the S phase accompanied 
with reduced percentages of cells at the G0/G1 and G2/M phases (Fig. 2A). CDDP induced 
accumulation of THP-1 cells at the G2/M in the sample treated with concentration of 1 µM, 
which turned into accumulation at the S phase in the sample subjected to 3 µM, and then in a 
concentration-dependent manner gradually slipped at the G0/G1 cell cycle arrest (Fig. S9, 
ESI). These results indicate that H8qasesc and CDDP exhibit different mechanisms of 
activity on THP-1 cell line. In AsPC-1 cells H8qasesc stimulated accumulation of cells at the 
S phase only at the lowest applied concentration, while increase of its concentration arrested 
the cell division at the G0/G1 phase (Fig. 2B).  
2.6. Apoptosis induced by H8qasesc was highly caspase-dependent but without 
activation of caspase-8 and -9 
To determine whether apoptosis induced by H8qasesc and CDDP was driven by caspase-
dependent pathway or not, we performed 6 h treatment of THP-1 cells with H8qasesc and 
CDDP applied at their ED50 concentrations, concomitantly incubated or not with pan-caspase 
inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethyl ketone (Z-VAD-fmk). The 
proper concentration of Z-VAD-fmk (10 µM), not toxic to THP-1 cells, was determined 
before the experiment. After incubation was ended, treated cells were stained with Annexin-
V/PI, and percentage of change in cell death events in Z-VAD-fmk co-treated cells in regard 
to Z-VAD-fmk non-treated cells was calculated for each labeled feature independently. As it 
could be seen in Fig. 3, inhibition of caspases activity reduced the both modalities of cell 
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death induced by H8qasesc and CDDP. It is known that caspases have no role in process of 
necrotic death, thus reduced percentage of PI single-stained events by Z-VAD-fmk indicates 
that necrotic cells recorded in Z-VAD-fmk non-treated samples actually originated from cells 
which initially entered apoptosis. This result signifies that necrosis, although seen in a very 
small percent in THP-1 cells incubated for 24 h with H8qasesc and CDDP, came out as a 
result of aponecrosis, that was inhibited by Z-VAD-fmk almost by the same percent in the 
samples treated with these two compounds. However, impact of co-treatment with Z-VAD-
fmk on process of apoptosis induced by H8qasesc and CDDP was quite different. In cells 
treated with H8qasesc, inhibition of caspases reduced development of early apoptotic events 
for 66 ± 16%, and 29 ± 1% of double-stained events. On the other hand, Z-VAD-fmk reduced 
incidence of early apoptosis by 28 ± 4% and 14 ± 6% of those in advanced stages of 
apoptotic death in CDDP co-treated samples.  
 
Fig. 3. Role of caspases activity in cell death induced by H8qasesc and CDDP. Percentages 
of early apoptosis (white bars), advanced apoptosis (gray bars) and necrosis (black bars) 
inhibition induced by 6 h co-incubation of pancaspase inhibitor Z-VAD-fmk with H8qasesc 
and CDDP applied in ED50 concentrations.  Results are expressed as the mean ± SD of two 
replicates from independent experiments. 
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The next step was to designate which apoptotic pathway was triggered in THP-1 cells 
treated with H8qasesc and CDDP. Non-treated controls and cells which underwent treatment 
with those two compounds applied at their ED50 concentration in 6 h were evaluated for 
caspase-8 and -9 activities. Results of this assay should reveal whether H8qasesc and CDDP 
initiate apoptosis by activation of extracellular death receptors, or by intrinsic pathway and 
consecutive activation of caspase-9. There was a low elementary caspase-9 activity found in 
control samples that points to metabolic or bioenergetics impairments as the underlying cause 
of spontaneous apoptosis in THP-1 cells (Fig. S10, ESI). Treatment with H8qasesc, however, 
did not increase activity of caspase-9 compared to non-treated controls, while activity of 
caspase-8 in H8qasesc-treated cells was below control levels. CDDP also induced discrete 
alterations in activity of evaluated caspases that may be described as a modest activation of 
caspase-8 above the level seen in the non-treated control samples.  
2.7. H8qasesc can induce CSC reprogramming in AsPC-1 cells 
AsPC-1 cells were incubated for 72 h with or without treatment with 1 and H8qasesc applied 
in concentrations of 1 and 10 µM. Treated and non-treated cells were stained with anti-CD44-
FITC and anti-CD133-PE in order to evaluate possible changes in expression of these two 
most commonly evaluated surface markers on cancer stem cells. According to non-treated 
samples AsPC-1 cells are displaying CD44+/CD133‒ phenotype, with almost all cells positive 
for CD44 expression (median fluorescence intensity, MFI = 3173 ± 376). Both compounds 
induced changes in CD44 expression in treated cells, while expression of CD133 was not 
affected by either of two tested treatments (Fig. 4). Incubation with 1 and H8qasesc in 
concentrations of 10 µM, gave almost the same results regarding both percent of CD44+ cells 
and MFI determined for CD44+ subpopulation (2419 ± 235 in 1 and 2539 ± 185 in H8qasesc-
treated cells). However, 1 in concentration of 1 µM induced greater reduction in percent of 
CD44+ cells, with asymmetrical positively skewed distribution and MFI of 2637 ± 272. It is 
obvious that although treatment with 1 µM of 1 notably reduced percentage of CD44+ cells, 
MFI value that represents median density of expressed CD44 per cell was higher in this 
population compared to the samples treated with 10 µM of 1. However, the greatest reduction 
in CD44 expressing cells was achieved by the treatment with H8qasesc at 1 µM. This 
population of cells was symmetrically distributed with significantly reduced MFI of 1800 ± 
93 in CD44+ subpopulation. 
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Fig. 4. Pro-differentiation activity of H8qasesc and 1. Changes in CD-44 expression on 
AsPC-1 cells after 3-day treatment with H8qasesc and 1 applied in two concentrations. 
Results are represented as the mean ± SD of two replicates. Treatments did not induce any 
change in expression of CD-133. 
 
2.8. Plasmid DNA interaction study 
The nuclease abilities of H8qasesc and 1 in the absence of any reducing agents were 
investigated using electrophoretic analysis on pUC19 plasmid incubated with increasing 
concentrations of investigated compounds. As represented in Fig. 5, electrophoresis of non-
treated plasmid pUC19 (lane 1 on both gels) resulted in formation of a strong band of 
supercoiled DNA (FI) and pale band of nicked plasmid form (FII). Treatment of pUC19 with 
H8qasesc in the concentration range 0.125–0.875 mM did not induce any variations in neither 
FI nor FII bands compared to non-treated control. On the other hand, 1 applied already at its 
lowest concentration of 0.125 mM induced discrete smudging but not accompanied with 
accelerated intensity of FII form (Fig. 5B, lane 2). Further rise in the concentration of 1 
resulted in smear formation together with gradual vanishing of FI form. This result shows 
that plasmid DNA was massively concentration-dependent degraded by 1, thus the complex 
possesses  a strong nuclease activity. Also, starting from 0.25 mM of 1 some amount 
aggregated plasmid DNA has been seen at the edge of the sample well. This aggregation 
might be explained by the formation of multiple hydrogen bonds between the complex cation 
of 1 and phosphate moieties of plasmid DNA. The similar interactions were observed 
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between the complex cation and perchlorate anion in the crystal structure of 1, since 
perchlorate anion as a phosphate DNA groups has a tetrahedral geometry. The aggregates 
were progressively fading away following increase in concentration of 1 most probably as a 
result of nuclease activity of the complex.  
 
Fig. 5. Agarose gel electrophoresis of interaction of pUC19 with H8qasesc (A) and complex 
1 (B). The interactions were investigated by incubation for 90 min of 460 ng plasmid in 20 
µL of 40 mM bicarbonate buffer (pH 8.4) at 37 °C, with different concentrations of H8qasesc 
and 1. Lane 1 – control plasmid pUC19; lanes 3‒8: pUC19 with 0.125, 0. 25, 0.375, 0.5, 
0.625, 0.75 and 0.875 mM concentration of H8qasesc (A) and 1 (B). 
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2.9. Docking studies to DNA and human serum albumin (HSA) 
Molecular docking is extremely useful tool in drug discovery to understand the drug–
biological target interactions and to investigate the potential binding mode and energy. In our 
docking study, to examine the binding of the ligand H8qasesc and complex 1 to DNA, the 
duplex of the sequence d(CGCGAATTCGCG)2 (PDB ID: 3U2N)
38
 was used. In silico 
molecular docking experiment revealed that the docked ligand H8qasesc showed absolute 
preference for minor groove binding (Fig. 6A), with binding energies in the range ‒27.2 to 
‒29.3 kJ mol‒1. No intercalation positions were found. The established interactions between 
H8qasesc and DNA nucleotides are hydrogen bonds (Fig. 6B). This is expected since 
H8qasesc consists of groups that are hydrogen bond donors (particularly NH and NH2 
groups), as well as hydrogen bond acceptors (the quinoline nitrogen atom). On the other 
hand, molecular docking of 1 gave conformations binding to both minor and major groove, 
with the preference for the major groove (Fig. 6C). Differences between best docking 
positions in major and minor groove are in the range 0.418‒0.836 kJ mol‒1. No intercalating 
structures were found. Interactions of the complex 1 with DNA are similar to those reported 
for the ligand. Additionally, aromatic systems from the coordinated ligands tend to form 
CH‒π interactions with DNA bases (Fig. 6D). 
 
 
 
Page 18 of 29MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
06
 Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 C
ol
le
ge
 L
on
do
n 
on
 0
6/
06
/2
01
6 
17
:0
0:
31
. 
View Article Online
DOI: 10.1039/C6MD00199H
19 
 
 
Fig. 6. (A) H8qasesc docking conformations. (B) H8qasesc ‒ minor groove DNA marked 
interactions. (C) The complex 1 docking conformations. (D) 1 ‒ major groove DNA marked 
interactions.  Dodecamer of the sequence d(CGCGAATTCGCG)2 (PDB ID 3U2N)
38 was 
used. Color code for interactions: green - hydrogen bonds; grey - aromatic interactions. 
HSA is best known for its ligand binding capacity. It provides a repository for an 
extraordinarily diverse range of molecules which makes it an important factor in the 
pharmacokinetic behavior of many drugs by affecting their efficiency and rate of delivery.39  
Additionally, the feature of HSA to accumulate in solid tumors raises interest of medicinal 
chemists to explore ability of newly synthesized compounds to bind to and use HSA as a 
carrier, and yields the rationale for developing the albumin-based drug delivery systems for 
tumor targeting drugs.40 Here we performed a docking analysis protocol to obtain information 
on H8qasesc and 1 interaction with HSA. 
Docking of H8qasesc into HSA showed preference to earlier reported heme binding 
pocket41-43 (Fig. S11A, ESI) instead of site II near Trp 214, where 1 is found to bind (Fig. 
S11B, ESI). Calculated binding energy of ‒32.6 kJ mol‒1 suggests significant interaction of 
the ligand H8qasesc with HSA. Quantified interactions of 1 with amino acid residues in 
binding site of HSA are given in Table S5 (ESI). 
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2.10. General discussion 
In this work, we report synthesis of novel Co(III) complex with H8qasesc ligand. 
Both compounds were characterized with single crystal XRD. Structure of 1 in solid state 
revealed that two molecules of ligand were NNSe tridentately coordinated to Co(III) ion. 
Every ligand molecule forms one 5-membered and 6-membered chelate ring. NMR studies 
indicate the same coordination mode in solution. 
Although the activity of the ligand on several cancer cell lines was previously 
investigated, due to differences in applied methodologies it is not possible to compare our 
current results with the previously published data.3 While colorimetric MTT assay allows the 
observation of reduced proliferation rates of treated cells in regard to non-treated ones, it does 
not provide the insight into reasons why treated cells have been decreased in number, on the 
other hand, Annexin-V/PI double staining gives direct assessment to the information about 
the magnitude and type of cell death induced. Currently applied methodological approach 
also includes information on cell death and cell cycle changes both gained on the very same 
treated cell population, giving the opportunity for an accurate observation of variations in 
those two parameters induced by different concentrations of investigated compounds. 
Therefore, instead to declare for activity of investigated treatments just according to relative 
number of viable cells in treated samples, we can also review their profiles of activity. 
CDDP, H8qasesc, and 1, which we evaluated in the current study, make a perfect trio, 
considering that each of them illustrates a distinctive mode of anticancer activity. 
 
The CDDP, used here as a reference compound, is nowadays the most efficient metal 
complex for the treatment of various types of cancer. Even though the Food and Drug 
Administration does not approve it for the first-line treatment of acute leukemia, laboratory 
and clinical investigations report its ability to induce apoptosis in leukemia cells and even 
remission in some aggressive forms of leukemia.44, 45 Current results show that CDDP 
concentration-dependently initiated apoptosis in THP-1 cell line, but almost all of the cells 
persisted in the early phase of apoptotic death at the end of 24 h incubation period. 
Subsequent cell cycle analysis offered some clues to understand reaction of THP-1 cells to 
the CDDP treatment. In spite of the fact that CDDP exerts various mechanisms that affect 
survival of malignant cells, the most important of them is its ability to create DNA lesions.46-
48 The majority of those DNA injuries are intrastrand cross-links which can be bypassed by 
activation of translesion synthesis polymerases during DNA replication, which are able to 
Page 20 of 29MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
06
 Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 C
ol
le
ge
 L
on
do
n 
on
 0
6/
06
/2
01
6 
17
:0
0:
31
. 
View Article Online
DOI: 10.1039/C6MD00199H
21 
 
accommodate bulky lesions. On the contrary, interstrand cross-links, which account for a few 
percentage of CDDP adducts, cannot be bypassed since these cause features such as extrusion 
of the cytosines of the cross-link sites, bending the helix axis towards the minor groove and 
large DNA unwinding,49 whereas their correction involves a complex interplay between a 
series of DNA repair pathways.50 According to our results, accumulations of cells at the G2 
check point and the S phase found in samples treated with lower concentrations were caused 
by obstacles during DNA synthesis, but in these samples apoptosis has not been initiated. 
Starting from the samples treated with CDDP at concentration of 10 µM and higher, there 
were synchronized appearance of cells at the G1-to-S arrest and early apoptotic events, which 
percentages were concurrently increasing in a concentration-dependent manner. It is obvious 
that the cells treated with CDDP in low concentrations were not halted to start DNA 
replication, although those were passing through the S phase more slowly than non-treated, 
undamaged cells. CDDP applied in higher concentrations obviously induced DNA damage in 
extent that was increasing concentration-dependently. Therefore, those cells were arrested by 
activation of G1-to-S checkpoint, which initiates complex network of repair pathways in 
order to maintain genomic integrity.51 Even though it has never been demonstrated, it is 
logically to expect that the incidence of interstrand cross-links increases with the rise of 
CDDP concentration on cells. Also, it is not known for how long cells affected by CDDP 
treatment can idle at the G1-to-S arrest before apoptosis is finally initiated, but our results 
indicate that CDDP-treated cells, even after exposure of phosphatidylserine, procrastinated 
the execution phase of apoptotic process for quite some time. All these facts correspond with 
relatively poor percent of inhibited apoptosis by co-treatment with Z-VAD-fmk accompanied 
with high percent of inhibited necrosis. The lack of elevated caspase-8 and -9 activities found 
after 6 h might be due to a short incubation time, but we previously reported that even after 
24 h of incubation CDDP did not induce pan-caspase activation in H460 cells.3 
A successful anticancer agent is expected not only to elicit apoptosis, but to initiate 
the triggering event(s) that would drive the chains of cascaded actions within a short period 
of time, leading treated cells throughout the whole process of programmed cell death starting 
from its initiation, execution, and finally termination. Our results indicate that H8qasesc 
maybe meets those requirements. Contrary to CDDP, this compound is powerful apoptosis 
inducer in THP-1 cells, which easily drove them throughout the course of programmed cell 
death. Although we yet do not have detailed knowledge about the mechanisms of H8qasesc 
activity on THP-1 cells, regarding the changes in cell cycle progression, H8qasesc also 
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interferes with the process of DNA synthesis. It is important to notice that the treatment with 
H8qasesc did not stimulate formation of cell cycle arrest but only extended the time cells 
spent at the S phase, which means that treated cells most probably did not activate 
multifaceted repair pathways. This clearly signifies that H8qasesc and CDDP do not share the 
same mechanism of activity. However, DNA docking analysis revealed that H8qasesc is a 
minor groove binder with no intercalating properties, while experimental results with pUC19 
showed that H8qasesc did not display nuclease activity on plasmid DNA. On the other hand, 
treatment with H8qasesc also did not stimulate activation of either caspase-8 or -9. However, 
result provided after co-incubation with pan-caspase inhibitor revealed that apoptosis induced 
by H8qasesc is highly caspase-dependent, suggesting that some other caspase than caspase-8 
or -9 might be responsible for regulation of apoptosis induced by H8qasesc. For that matter, it 
is very possible that caspase-2 was involved knowing it can be activated due to formation of 
free radical species, DNA-damage, or cytoskeletal disruption,52 which should be further 
investigated. It is important to underline that the results on DNA were either theoretical in the 
case of docking analysis or gained in in vitro model that was depleting regular nuclear DNA 
milieu. Thus, our results provide information on possible H8qasesc interactions while for the 
exact conformation of the H8qasesc with his targets, additional experiments on intact cells 
will be needed. Also, at this point we cannot be sure that H8qasesc does not experience 
structural alteration(s) due to enzymatic transformation either in serum or in targeted cells. It 
would be of special importance to determine percentage of HSA occupied by H8qasesc in the 
human serum, as well as the type of interaction being it irreversible or competitive. Those 
parameters will be helpful in predicting a possible effect on transport and metabolism of 
heme that might be induced by the treatment with H8qasesc. 
Complexation of H8qasesc with Co has resulted in compound with quite different 
properties. Already at the first screening on THP-1 cell line it was obvious that 1 displays 
aggressive mode of activity, inducing necrosis and apoptosis. Its intrinsic toxicity was further 
confirmed in a range of several times lower concentrations. However, its ED50 value 
computed from one replicate, carried on THP-1 cells, is almost the same as that of H8qasesc, 
and more importantly it is several times lower compared to ED50 achieved by CDDP. 
Considering that the aim of our investigation was to determine ability of H8qasesc and 1 to 
induce apoptosis in 24 h with CDDP as a referent compound, H8qasesc and its Co complex 
might be proclaimed as very successful anticancer agents just relying on ED50 concentrations. 
How actually Pd(II) and Pt(II) complexes increase anticancer potency of H8qasesc, as well as 
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do those two metals significantly change the favorable mode of H8qasesc activity should be 
investigated in the next round, but all three metals have in common to drastically reduce the 
free radical-scavenging activity of H8qasesc.3 Additionally, we demonstrated that 1 displayed 
vigorous nuclease activity on plasmid pUC19, completely digesting its DNA in 
concentration-dependent manner. 
Results obtained on THP-1 cell line are representing the baseline evidence on pro-
apoptotic activity of investigated compounds. Nevertheless, we were far more curious on how 
the investigated compounds will affect survival of AsPC-1 cells. As we briefly reviewed 
above, AsPC-1 cell line is categorized as CSCs. Those are poorly differentiated, fast dividing, 
self-renewing cells, which sustain the long-term clonal maintenance of the neoplasm. CSCs 
are highly resistant to pro-apoptotic agents, with unique ability to stop dividing and “hide” 
into the state of dormancy while escaping the harmful impact of an efficient anti-cancer 
agent. While neither CDDP nor 1 did induce cell death in AsPC-1 treated cells, H8qasesc 
generated apoptotic response in its highest applied concentration. More interestingly, only 
H8qasesc treatment at its lowest concentration induced accumulation of AsPC-1 cells at the S 
phase, while in all other samples cells were arrested at the G0/G1 phase. Although additional 
experiments do remain necessary to confirm that AsPC-1 cells are shifted into a dormant 
state, for example by determining the proportion of cells within G0 phase by lack of cyclin-E 
expression, the level of probability of dormancy rises with the facts that there was not a 
significant concentration-dependent variation in the magnitude of the arrest. Therefore, the 
G0/G1 arrest found in samples treated with H8qasesc already at concentration of 10 µM 
means that AsPC-1 cells were distressed but successfully resisted to apoptotic stimuli up to 
the concentration of 100 µM when the pro-apoptotic triggering mechanism became too strong 
to be ignored.  
CD44 is a multifunctional class I transmembrane glycoprotein involved in 
lymphocyte activation, recirculation and homing, adhesion of extracellular matrix, 
angiogenesis, and cell proliferation, differentiation, and migration.53, 54 It is also involved in 
numerous complex-signaling cascades, while reacting with osteoponin regulates its cellular 
function leading to tumor progression. Differentiation in breast CSCs by knockdown of 
CD44 showed dramatically changed gene expression pattern in treated cells compared to 
original cells.55 Hong et al demonstrated that CD44+ cells are responsible for the resistance to 
gemcitabine in pancreatic cancer.56 The same authors reported on positive correlation 
between CD44 expression with histological grade and poor prognosis. All these facts clearly 
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demonstrate the significance of CD44 down expression in AsPC-1 cells. Our results revealed 
that 3-day incubation with 1 achieved percentage of CD44+ cells, but in the same time 
average expression of CD44 receptors per cell in CD44+ subpopulation was not remarkably 
reduced. This implies that remaining CD44+ cells retained their phenotypic character. Quite 
contrary, treatment with H8qasesc in lower tested concentration successfully reduced 
percentage of CD44+ cells together with strikingly decreased expression of targeted protein 
on the membranes of CD44+ subpopulation.  
 
 
3. CONCLUSION 
Activity of H8qasesc on two diverse cell lines demonstrated ligand’s ability to induce 
apoptotic death in more than a half treated non-CSC cells already at concentration of 10 µM. 
This apoptotic response was shown to be highly caspase-dependent, but did not include 
activation of either caspase-8 or -9. In CSC model, treatment with H8qasesc at 100 µM 
triggered apoptosis in a highly resistant AsPC-1 cell line, while at low concentration the 
ligand successfully caused the change in their phenotype. Our results clearly indicate that 
with dose titration of H8qasesc it can be expected to achieve apoptotic death of non-CSC and 
CSC, or CSC differentiation, which would make them more vulnerable to pro-apoptotic 
drugs. In spite of our expectations, complexation of H8qasesc with Co(III) did not result in a 
compound with outstanding properties. The complex 1 displayed strong, but toxic response 
on THP-1 cell line with lack of ability to trigger death in CSCs. Its vigorous nuclease activity 
may be the relying cause of high incidence of necrosis seen in the treated samples. Finally, 
the excellent activity profile of H8qasesc reviewed herein deserves its further evaluation in 
terms of antineoplastic agent with expanded spectrum of actions. 
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Graphical abstract and synopsis 
 
Selenosemicarbazone ligand and its Co(III)-based complex were characterized by X-ray analysis. 
Apoptosis triggered by the ligand was highly caspase-dependent. The ligand initiated reprogramming of 
cancer stem cells phenotype in AsPC-1 cell line. The complex concentration-dependently digested 
plasmid DNA which might be the cause of its cytotoxic activity. 
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